Y-Mabs Therapeutics Profit Margin

The latest profit margin for YMAB is -26.03% as of June 2025. That compares with -28.44% in the prior-year period — up 8.5% year over year. That is below the Healthcare sector average of 21.34%. Investors often review this figure alongside Y-Mabs Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, YMAB's profit margin moved from -28.44% to -26.03% — a 8.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Y-Mabs Therapeutics's valuation or profitability profile.

Against Healthcare companies, YMAB currently prints -26.03% for profit margin, while the sector average sits near 21.34%. That is roughly 222.0% below the sector mean. Large gaps often invite a closer look at Y-Mabs Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Y-Mabs Therapeutics converts resources into returns. At -26.03%, YMAB may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -28.44% in the prior-year period — up 8.5% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting YMAB's profit margin (-26.03%), review year-over-year change from -28.44%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.